The in silico analysis of data bases showed that SORT1 mRNA expression levels were significantly elevated in high‐risk patient groups characterized by the worst survival, disease‐free survival (DFS) and relapse‐free survival (RFS), who are at the highest risk of developing new tumours after treatments (Figure 5A‐C). This evidence concerns the gene SORT1 and neoplasm.